Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Tauopathies Clear all
Completed No phase listed Observational

Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)

NCT05364307
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Prescreener database
Other
Lead sponsor
Global Alzheimer's Platform Foundation
Other
Eligibility
50 Years to 90 Years
Enrollment
1,555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
San Diego, California • Santa Ana, California • Aventura, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Jul 22, 2026, 3:33 AM EDT
Completed No phase listed Observational

The Effect of De-Prescribing Antipsychotics on Health and Quality of Life for People With Dementia

NCT05172687
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Prescribing, Off-Label
Interventions
Overprescribing letter to attributed physician, Placebo letter to attributed physician
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
336,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Cambridge, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Jul 22, 2026, 3:33 AM EDT
Recruiting Phase 2 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

NCT06808984
View directory record Official record
Conditions
Agitation, Alzheimer Disease
Interventions
BMS-986368, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
55 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
53
States / cities
Homewood, Alabama • Huntsville, Alabama • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 22, 2026, 3:33 AM EDT
Completed Phase 1 Interventional Results available

A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease

NCT00988598
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04447943, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Glendale, California • Gainesville, Florida • Hallandale, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Jul 22, 2026, 3:33 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol

NCT07012993
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia, Healthy Volunteers
Interventions
18F-Florbetapir or 18F-Flutemetamol
Drug
Lead sponsor
Akiva Mintz
Other
Eligibility
18 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 22, 2026, 3:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study of LY2811376 Single Doses in Healthy Subjects

NCT00838084
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY2811376, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2009 · Synced Jul 22, 2026, 3:33 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease

NCT00555204
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABT-089, placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
55 Years to 90 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
42
States / cities
Phoenix, Arizona • Sun City, Arizona • Fresno, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Jul 22, 2026, 3:33 AM EDT
Completed Not applicable Interventional

Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease

NCT02958930
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease, Late Onset
Interventions
MemorEM 1000
Device
Lead sponsor
NeuroEM Therapeutics, Inc.
Industry
Eligibility
63 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Jul 22, 2026, 3:33 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Study to Understand Novel Biomarkers in Researching Dementia

NCT06547099
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
Clinical tau PET, Clinical amyloid test, Research blood collection, Cognitive assessments
Diagnostic Test · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jul 22, 2026, 3:33 AM EDT
Recruiting Not applicable Interventional

Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease

NCT06484244
View directory record Official record
Conditions
Alzheimers Disease, Mild Cognitive Impairment
Interventions
5 Sessions of Split-belt Treadmill-based Locomotor Adaptation
Other
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 22, 2026, 3:33 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD

NCT05881239
View directory record Official record
Conditions
Subjective Cognitive Concerns, Mild Cognitive Impairment, Mild Behavioral Impairment, Healthy Aging
Interventions
AROMHA Brain Health Test
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 22, 2026, 3:33 AM EDT
Active, not recruiting Phase 2 Interventional

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

NCT04270175
View directory record Official record
Conditions
Amyloid, AL Amyloidosis, Refractory AL Amyloidosis
Interventions
Daratumumab SC, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 22, 2026, 3:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls

NCT01348061
View directory record Official record
Conditions
Alzheimer Disease, Progressive Supranuclear Palsy
Interventions
Not listed
Lead sponsor
KineMed
Industry
Eligibility
50 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
3
States / cities
Glendale, California • Eatontown, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Jul 22, 2026, 3:33 AM EDT
Terminated Phase 2 Interventional Results available

Study of ASN51 in Adults With Early Alzheimer's Disease

NCT06677203
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ASN51, Placebo
Drug
Lead sponsor
Asceneuron S.A.
Industry
Eligibility
50 Years to 80 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
7
States / cities
Clermont, Florida • Lady Lake, Florida • Maitland, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Jul 22, 2026, 3:33 AM EDT
Completed Phase 2 Interventional

Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease

NCT01254773
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Experimental Bapineuzumab
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 89 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
28
States / cities
Tucson, Arizona • La Habra, California • Lomita, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jul 22, 2026, 3:33 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

NCT05361382
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-Flortaucipir radiopharmaceutical, 18F-MK-6240 radiopharmaceutical, Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)
Drug
Lead sponsor
Tharick Pascoal
Other
Eligibility
18 Years to 90 Years
Enrollment
822 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
7
States / cities
Berkeley, California • San Francisco, California • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 22, 2026, 3:33 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

TMS in Preclinical and Prodromal AD: Modulation of Brain Networks and Memory

NCT04294888
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Aging
Interventions
repetitive transcranial magnetic stimulation (rTMS)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 22, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)

NCT01595646
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Saline, Insulin detemir, Insulin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 89 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Jul 22, 2026, 3:33 AM EDT
Terminated No phase listed Observational

Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects

NCT01018927
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Administering three additional MRI images
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Jul 22, 2026, 3:33 AM EDT
Completed Not applicable Interventional Results available

Reducing CVD Risk in Caregivers: A Brief Behavioral Activation Intervention

NCT01802554
View directory record Official record
Conditions
Depressive Symptoms, Inflammation
Interventions
Pleasant Events Program (PEP), Information Support (IS)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
55 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Jul 22, 2026, 3:33 AM EDT
Completed Phase 1 Interventional Results available

Tau Imaging in Professional Fighters

NCT02278354
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Jul 22, 2026, 3:33 AM EDT
Completed No phase listed Observational

Feasibility of Passive Data Collection in Dementia Subjects With Agitation

NCT04413851
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Vascular Dementia, Frontotemporal Dementia, Lewy Body Dementia, Mixed Dementia
Interventions
Not listed
Lead sponsor
HealthMode Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Tucson, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Jul 22, 2026, 3:33 AM EDT
Active, not recruiting Not applicable Interventional

ED-LEAD: Emergency Departments Leading the Transformation of Alzheimer's and Dementia Care

NCT06079203
View directory record Official record
Conditions
Alzheimer's Disease Related Dementia, Alzheimer Disease
Interventions
Emergency Care Redesign (ECR), Nurse-led Telephonic Care (NLTC), Community Paramedic-led Transitions Intervention (CPTI)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
66 Years and older
Enrollment
19,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 22, 2026, 3:33 AM EDT
Not listed Phase 2 Interventional

Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE)

NCT04004702
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Levetiracetam
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Jul 22, 2026, 3:33 AM EDT